Hims & Hers Health, Inc. $HIMS Shares Bought by Sunbelt Securities Inc.

Sunbelt Securities Inc. grew its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 5,444.7% in the first quarter, according to its most recent disclosure with the SEC. The fund owned 23,565 shares of the company’s stock after buying an additional 23,140 shares during the period. Sunbelt Securities Inc.’s holdings in Hims & Hers Health were worth $489,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in HIMS. Binnacle Investments Inc purchased a new position in shares of Hims & Hers Health during the third quarter worth about $28,000. Silicon Valley Capital Partners purchased a new stake in Hims & Hers Health during the 3rd quarter valued at approximately $48,000. Flagship Harbor Advisors LLC acquired a new stake in Hims & Hers Health during the 4th quarter worth approximately $28,000. Bogart Wealth LLC lifted its position in Hims & Hers Health by 235.8% during the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after acquiring an additional 632 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its position in Hims & Hers Health by 273.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock worth $47,000 after acquiring an additional 687 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

Wall Street Analyst Weigh In

HIMS has been the topic of a number of recent research reports. Jefferies Financial Group set a $24.50 target price on Hims & Hers Health in a report on Tuesday, May 12th. Wall Street Zen downgraded Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Truist Financial lifted their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research report on Friday, July 24th. UBS Group set a $23.00 price objective on shares of Hims & Hers Health in a research report on Friday, May 22nd. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $25.00 price objective on shares of Hims & Hers Health in a research note on Tuesday, May 5th. Four analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Hims & Hers Health has a consensus rating of “Hold” and an average target price of $31.43.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, insider Irene Becklund sold 7,573 shares of the business’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $30.25, for a total transaction of $229,083.25. Following the sale, the insider directly owned 11,280 shares in the company, valued at approximately $341,220. The trade was a 40.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Michael Chi sold 14,027 shares of the company’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $31.50, for a total transaction of $441,850.50. Following the transaction, the chief operating officer directly owned 432,124 shares in the company, valued at approximately $13,611,906. This trade represents a 3.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 83,126 shares of company stock valued at $2,711,339 in the last three months. Insiders own 11.76% of the company’s stock.

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: One bullish analysis argues that Hims & Hers remains undervalued, citing projected revenue growth, approximately 73% gross margins, accelerating subscriber additions, GLP-1 and peptide demand, international expansion, and the Novo Nordisk partnership. The thesis suggests substantial long-term upside if the company sustains growth despite the regulatory controversy. Hims & Hers Health: Still an Undervalued Company With Tremendous Upside
• Neutral Sentiment: Several law firms, including SBS Law, Kaplan Fox, Howard G. Smith, and Holzer & Holzer, announced investigations into possible securities-law violations. These announcements are typically investor-solicitation notices and do not establish wrongdoing, but they raise the possibility of shareholder litigation and additional disclosure obligations. SBS Law Investigation
• Negative Sentiment: The FTC alleges Hims & Hers shared customers’ health information with advertising platforms including Meta and Snap, failed to clearly disclose prescription charges, and used potentially deceptive billing and privacy practices. The lawsuit could lead to penalties, higher compliance expenses, tighter restrictions on marketing, and damage to consumer trust. Media coverage of the action contributed to a sharp decline in the shares and remains the principal near-term risk for HIMS. FTC Sues Hims & Hers

Hims & Hers Health Price Performance

Shares of HIMS opened at $27.79 on Friday. Hims & Hers Health, Inc. has a twelve month low of $13.74 and a twelve month high of $70.43. The stock’s 50 day moving average is $31.23 and its two-hundred day moving average is $26.12. The firm has a market capitalization of $6.43 billion, a PE ratio of -308.74, a P/E/G ratio of 76.10 and a beta of 2.35. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of 2.18.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.44). The business had revenue of $608.10 million for the quarter, compared to analyst estimates of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The business’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.20 EPS. Research analysts anticipate that Hims & Hers Health, Inc. will post 0.03 earnings per share for the current year.

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.